161 related articles for article (PubMed ID: 18296119)
21. [Mean platelet volume: interactions with platelet aggregation activity and glycoprotein IIb-IIIa and Ib expression levels].
Khaspekova SG; Ziuriaev IT; Iakushkin VV; Naĭmushin IaA; Sirotkina OV; Zaĭtseva NO; Ruda MIa; Mazurov AV
Biomed Khim; 2014; 60(1):94-108. PubMed ID: 24749250
[TBL] [Abstract][Full Text] [Related]
22. Platelet hyperactivity in type 2 diabetes: role of antiplatelet agents.
Natarajan A; Zaman AG; Marshall SM
Diab Vasc Dis Res; 2008 Jun; 5(2):138-44. PubMed ID: 18537103
[TBL] [Abstract][Full Text] [Related]
23. New therapeutic approaches to combat arterial thrombosis: better drugs for old targets, novel targets, and future prospects.
Choi J; Kermode JC
Mol Interv; 2011 Apr; 11(2):111-23. PubMed ID: 21540471
[TBL] [Abstract][Full Text] [Related]
24. Inhibitory effects of glycoprotein IIb/IIIa antagonists and aspirin on the release of soluble CD40 ligand during platelet stimulation.
Nannizzi-Alaimo L; Alves VL; Phillips DR
Circulation; 2003 Mar; 107(8):1123-8. PubMed ID: 12615789
[TBL] [Abstract][Full Text] [Related]
25. Inhibition of microsurgical thrombosis by the platelet glycoprotein IIb/IIIa antagonist SR121566A.
Ching S; Thoma A; Monkman S; Kelton JG
Plast Reconstr Surg; 2003 Jul; 112(1):177-85. PubMed ID: 12832891
[TBL] [Abstract][Full Text] [Related]
26. The contribution of thrombin-induced platelet activation to thrombus growth is diminished under pathological blood shear conditions.
Lee H; Sturgeon SA; Jackson SP; Hamilton JR
Thromb Haemost; 2012 Feb; 107(2):328-37. PubMed ID: 22187047
[TBL] [Abstract][Full Text] [Related]
27. New targets for antithrombotic drugs.
Thiagarajan P
Am J Cardiovasc Drugs; 2002; 2(4):227-35. PubMed ID: 14727968
[TBL] [Abstract][Full Text] [Related]
28. Antiplatelet therapies for the treatment of cardiovascular disease.
Michelson AD
Nat Rev Drug Discov; 2010 Feb; 9(2):154-69. PubMed ID: 20118963
[TBL] [Abstract][Full Text] [Related]
29. Antithrombotic effects of MK-0852, a platelet fibrinogen receptor antagonist, in canine models of thrombosis.
Ramjit DR; Lynch JJ; Sitko GR; Mellott MJ; Holahan MA; Stabilito II; Stranieri MT; Zhang G; Lynch RJ; Manno PD
J Pharmacol Exp Ther; 1993 Sep; 266(3):1501-11. PubMed ID: 8371153
[TBL] [Abstract][Full Text] [Related]
30. Current and future antiplatelet therapies: emphasis on preserving haemostasis.
McFadyen JD; Schaff M; Peter K
Nat Rev Cardiol; 2018 Mar; 15(3):181-191. PubMed ID: 29297508
[TBL] [Abstract][Full Text] [Related]
31. Ability of anti-glycoprotein IIb/IIIa agents to dissolve platelet thrombi formed on a collagen surface under blood flow conditions.
Goto S; Tamura N; Ishida H
J Am Coll Cardiol; 2004 Jul; 44(2):316-23. PubMed ID: 15261925
[TBL] [Abstract][Full Text] [Related]
32. The role of the platelet in the pathogenesis of atherothrombosis.
Steinhubl SR; Moliterno DJ
Am J Cardiovasc Drugs; 2005; 5(6):399-408. PubMed ID: 16259528
[TBL] [Abstract][Full Text] [Related]
33. Characterization of a novel function-blocking antibody targeted against the platelet P2Y1 receptor.
Karim ZA; Vemana HP; Alshbool FZ; Lin OA; Alshehri AM; Javaherizadeh P; Paez Espinosa EV; Khasawneh FT
Arterioscler Thromb Vasc Biol; 2015 Mar; 35(3):637-44. PubMed ID: 25593131
[TBL] [Abstract][Full Text] [Related]
34. 12-lipoxygenase: a potential target for novel anti-platelet therapeutics.
Yeung J; Holinstat M
Cardiovasc Hematol Agents Med Chem; 2011 Jul; 9(3):154-64. PubMed ID: 21838667
[TBL] [Abstract][Full Text] [Related]
35. [From the physiopathology of thrombosis to therapeutic targets].
Nurden P; Ndoko S; Nurden AT
Arch Mal Coeur Vaiss; 2001 Nov; 94(11 Suppl):1210-7. PubMed ID: 11794961
[TBL] [Abstract][Full Text] [Related]
36. Pharmacodynamic properties of antiplatelet agents: current knowledge and future perspectives.
Kalantzi KI; Tsoumani ME; Goudevenos IA; Tselepis AD
Expert Rev Clin Pharmacol; 2012 May; 5(3):319-36. PubMed ID: 22697594
[TBL] [Abstract][Full Text] [Related]
37. Recombinant GPVI-Fc added to single or dual antiplatelet therapy in vitro prevents plaque-induced platelet thrombus formation.
Mojica Muñoz AK; Jamasbi J; Uhland K; Degen H; Münch G; Ungerer M; Brandl R; Megens R; Weber C; Lorenz R; Siess W
Thromb Haemost; 2017 Aug; 117(8):1651-1659. PubMed ID: 28569920
[TBL] [Abstract][Full Text] [Related]
38. Pharmacological inhibition of platelet reactivity. Clinical and pharmacodynamic effects.
Vallés J; Moscardo A; Madrid I; Santos MT
Curr Vasc Pharmacol; 2013 Jul; 11(4):431-47. PubMed ID: 23905638
[TBL] [Abstract][Full Text] [Related]
39. Functional Relevance of the Anaphylatoxin Receptor C3aR for Platelet Function and Arterial Thrombus Formation Marks an Intersection Point Between Innate Immunity and Thrombosis.
Sauter RJ; Sauter M; Reis ES; Emschermann FN; Nording H; Ebenhöch S; Kraft P; Münzer P; Mauler M; Rheinlaender J; Madlung J; Edlich F; Schäffer TE; Meuth SG; Duerschmied D; Geisler T; Borst O; Gawaz M; Kleinschnitz C; Lambris JD; Langer HF
Circulation; 2018 Oct; 138(16):1720-1735. PubMed ID: 29802205
[TBL] [Abstract][Full Text] [Related]
40. Intravenous and oral antithrombotic efficacy of the novel platelet GPIIb/IIIa antagonist roxifiban (DMP754) and its free acid form, XV459.
Mousa SA; Kapil R; Mu DX
Arterioscler Thromb Vasc Biol; 1999 Oct; 19(10):2535-41. PubMed ID: 10521384
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
